These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 27199119)

  • 1. A myosin activator improves actin assembly and sarcomere function of human-induced pluripotent stem cell-derived cardiomyocytes with a troponin T point mutation.
    Broughton KM; Li J; Sarmah E; Warren CM; Lin YH; Henze MP; Sanchez-Freire V; Solaro RJ; Russell B
    Am J Physiol Heart Circ Physiol; 2016 Jul; 311(1):H107-17. PubMed ID: 27199119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Troponin destabilization impairs sarcomere-cytoskeleton interactions in iPSC-derived cardiomyocytes from dilated cardiomyopathy patients.
    Dai Y; Amenov A; Ignatyeva N; Koschinski A; Xu H; Soong PL; Tiburcy M; Linke WA; Zaccolo M; Hasenfuss G; Zimmermann WH; Ebert A
    Sci Rep; 2020 Jan; 10(1):209. PubMed ID: 31937807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential responses of induced pluripotent stem cell-derived cardiomyocytes to anisotropic strain depends on disease status.
    Chun YW; Voyles DE; Rath R; Hofmeister LH; Boire TC; Wilcox H; Lee JH; Bellan LM; Hong CC; Sung HJ
    J Biomech; 2015 Nov; 48(14):3890-6. PubMed ID: 26476764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An intermittent rocking platform for integrated expansion and differentiation of human pluripotent stem cells to cardiomyocytes in suspended microcarrier cultures.
    Ting S; Chen A; Reuveny S; Oh S
    Stem Cell Res; 2014 Sep; 13(2):202-13. PubMed ID: 25043964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic Regulation of Phosphodiesterases 2A and 3A Underlies Compromised β-Adrenergic Signaling in an iPSC Model of Dilated Cardiomyopathy.
    Wu H; Lee J; Vincent LG; Wang Q; Gu M; Lan F; Churko JM; Sallam KI; Matsa E; Sharma A; Gold JD; Engler AJ; Xiang YK; Bers DM; Wu JC
    Cell Stem Cell; 2015 Jul; 17(1):89-100. PubMed ID: 26095046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Sarcomere Activators and Inhibitors Targeting Myosin Cross-Bridges on Ca
    Halas M; Langa P; Warren CM; Goldspink PH; Wolska BM; Solaro RJ
    Mol Pharmacol; 2022 May; 101(5):286-299. PubMed ID: 35236770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serine biosynthesis as a novel therapeutic target for dilated cardiomyopathy.
    Perea-Gil I; Seeger T; Bruyneel AAN; Termglinchan V; Monte E; Lim EW; Vadgama N; Furihata T; Gavidia AA; Arthur Ataam J; Bharucha N; Martinez-Amador N; Ameen M; Nair P; Serrano R; Kaur B; Feyen DAM; Diecke S; Snyder MP; Metallo CM; Mercola M; Karakikes I
    Eur Heart J; 2022 Sep; 43(36):3477-3489. PubMed ID: 35728000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinatorial polymer matrices enhance in vitro maturation of human induced pluripotent stem cell-derived cardiomyocytes.
    Chun YW; Balikov DA; Feaster TK; Williams CH; Sheng CC; Lee JB; Boire TC; Neely MD; Bellan LM; Ess KC; Bowman AB; Sung HJ; Hong CC
    Biomaterials; 2015 Oct; 67():52-64. PubMed ID: 26204225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modelling diastolic dysfunction in induced pluripotent stem cell-derived cardiomyocytes from hypertrophic cardiomyopathy patients.
    Wu H; Yang H; Rhee JW; Zhang JZ; Lam CK; Sallam K; Chang ACY; Ma N; Lee J; Zhang H; Blau HM; Bers DM; Wu JC
    Eur Heart J; 2019 Dec; 40(45):3685-3695. PubMed ID: 31219556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy.
    Sun N; Yazawa M; Liu J; Han L; Sanchez-Freire V; Abilez OJ; Navarrete EG; Hu S; Wang L; Lee A; Pavlovic A; Lin S; Chen R; Hajjar RJ; Snyder MP; Dolmetsch RE; Butte MJ; Ashley EA; Longaker MT; Robbins RC; Wu JC
    Sci Transl Med; 2012 Apr; 4(130):130ra47. PubMed ID: 22517884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SarcTrack.
    Toepfer CN; Sharma A; Cicconet M; Garfinkel AC; Mücke M; Neyazi M; Willcox JAL; Agarwal R; Schmid M; Rao J; Ewoldt J; Pourquié O; Chopra A; Chen CS; Seidman JG; Seidman CE
    Circ Res; 2019 Apr; 124(8):1172-1183. PubMed ID: 30700234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe DCM phenotype of patient harboring RBM20 mutation S635A can be modeled by patient-specific induced pluripotent stem cell-derived cardiomyocytes.
    Streckfuss-Bömeke K; Tiburcy M; Fomin A; Luo X; Li W; Fischer C; Özcelik C; Perrot A; Sossalla S; Haas J; Vidal RO; Rebs S; Khadjeh S; Meder B; Bonn S; Linke WA; Zimmermann WH; Hasenfuss G; Guan K
    J Mol Cell Cardiol; 2017 Dec; 113():9-21. PubMed ID: 28941705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human-Induced Pluripotent Stem Cell-Derived Cardiomyocyte Model for
    Kondo T; Higo S; Shiba M; Kohama Y; Kameda S; Tabata T; Inoue H; Okuno S; Ogawa S; Nakamura S; Takeda M; Ito E; Li J; Liu L; Kuramoto Y; Lee JK; Takashima S; Miyagawa S; Sawa Y; Hikoso S; Sakata Y
    Circ Genom Precis Med; 2022 Oct; 15(5):e003522. PubMed ID: 35861968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omecamtiv mercabil and blebbistatin modulate cardiac contractility by perturbing the regulatory state of the myosin filament.
    Kampourakis T; Zhang X; Sun YB; Irving M
    J Physiol; 2018 Jan; 596(1):31-46. PubMed ID: 29052230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting cardiac myeloperoxidase alleviates the relaxation defect in hypertrophic cardiomyocytes.
    Ramachandra CJA; Kp MMJ; Chua J; Hernandez-Resendiz S; Liehn EA; Knöll R; Gan LM; Michaëlsson E; Jonsson MKB; Ryden-Markinhuhta K; Bhat RV; Fritsche-Danielson R; Lin YH; Sadayappan S; Tang HC; Wong P; Shim W; Hausenloy DJ
    Cardiovasc Res; 2022 Jan; 118(2):517-530. PubMed ID: 33705529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo differentiation of induced pluripotent stem cell-derived cardiomyocytes.
    Yu T; Miyagawa S; Miki K; Saito A; Fukushima S; Higuchi T; Kawamura M; Kawamura T; Ito E; Kawaguchi N; Sawa Y; Matsuura N
    Circ J; 2013; 77(5):1297-306. PubMed ID: 23392122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells.
    Han L; Li Y; Tchao J; Kaplan AD; Lin B; Li Y; Mich-Basso J; Lis A; Hassan N; London B; Bett GC; Tobita K; Rasmusson RL; Yang L
    Cardiovasc Res; 2014 Nov; 104(2):258-69. PubMed ID: 25209314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-Dependent Effects of the Myosin Activator Omecamtiv Mecarbil on Cross-Bridge Behavior and Force Generation in Failing Human Myocardium.
    Mamidi R; Li J; Gresham KS; Verma S; Doh CY; Li A; Lal S; Dos Remedios CG; Stelzer JE
    Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29030372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small molecule-mediated refolding and activation of myosin motor function.
    Radke MB; Taft MH; Stapel B; Hilfiker-Kleiner D; Preller M; Manstein DJ
    Elife; 2014 Feb; 3():e01603. PubMed ID: 24520162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure.
    Malik FI; Hartman JJ; Elias KA; Morgan BP; Rodriguez H; Brejc K; Anderson RL; Sueoka SH; Lee KH; Finer JT; Sakowicz R; Baliga R; Cox DR; Garard M; Godinez G; Kawas R; Kraynack E; Lenzi D; Lu PP; Muci A; Niu C; Qian X; Pierce DW; Pokrovskii M; Suehiro I; Sylvester S; Tochimoto T; Valdez C; Wang W; Katori T; Kass DA; Shen YT; Vatner SF; Morgans DJ
    Science; 2011 Mar; 331(6023):1439-43. PubMed ID: 21415352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.